secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001558370-24-009704
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ReShape Lifesciences announces reverse merger with Vyome Therapeutics and asset sale for $5.16M
--------------------------------------------------------------------------------

- Vyome stockholders will own 88.9% of combined company; ReShape stockholders to own 11.1%.
- ReShape sells substantially all assets to Ninjour (Biorad Medisys affiliate) for $5.16M cash; Merger closes immediately after.
- Series C Preferred liquidation preference reduced from $26.2M to at most $1M or 20% of asset sale price or excess net cash.
- Up to $7.3M in concurrent financing includes $5.8M common stock at 30% discount to post-merger valuation.
- CEO Paul Hickey receives severance increase to 18 months base salary and 4% fully diluted shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000155837024009704/0001558370-24-009704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000155837024009704/rsls-20240708x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer